{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:26:04Z","timestamp":1775503564135,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["FRN151290"],"award-info":[{"award-number":["FRN151290"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","award":["IA-035"],"award-info":[{"award-number":["IA-035"]}],"id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["#2015-703549"],"award-info":[{"award-number":["#2015-703549"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment\u2019s real-world effectiveness. We examined real-world population-based comparative effectiveness of second-line ipilimumab versus non-ipilimumab treatments (chemotherapy or targeted treatments).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a cohort of melanoma patients receiving systemic treatment for advanced disease since April 2005 from Ontario, Canada. Patients were identified from provincial drug databases and the Ontario Cancer Registry who received second-line ipilimumab from 2012 to 2015 (treated) or second-line non-ipilimumab treatment prior to 2012 (historical controls). Historical controls were chosen, to permit the most direct comparison to pivotal trial findings. The cohort was linked to administrative databases to identify baseline characteristics and outcomes. Kaplan-Meier curves and multivariable Cox regression models were used to assess overall survival (OS). Observed potential confounders were adjusted for using inverse probability of treatment weighting (IPTW).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 329 patients with metastatic melanoma (MM) who had received second-line treatments (189 treated; 140 controls). Patients receiving second-line ipilimumab were older (61.7\u2009years vs 55.2\u2009years) compared to historical controls. Median OS were 6.9 (95% CI: 5.4\u20138.3) and 4.95 (4.3\u20136.0) months for ipilimumab and controls, respectively. The crude 1-year, 2-year, and 3-year OS probabilities were 34.3% (27\u201341%), 20.6% (15\u201327%), and 15.2% (9.6\u201321%) for ipilimumab and 17.1% (11\u201323%), 7.1% (2.9\u201311%), and 4.7% (1.2\u20138.2%) for controls. Ipilimumab was associated with improved OS (IPTW HR\u2009=\u20090.62; 95% CI: 0.49\u20130.78;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world analysis suggests second-line ipilimumab is associated with an improvement in OS for MM patients in routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06798-1","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T06:03:05Z","timestamp":1586930585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada"],"prefix":"10.1186","volume":"20","author":[{"given":"Wei Fang","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn M.","family":"Beca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Croxford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanrudee","family":"Isaranawatchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines B.","family":"Menjak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa M.","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig C.","family":"Earle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Gavura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin K.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"6798_CR1","doi-asserted-by":"publisher","unstructured":"Lakdawalla DN, Shafrin J, Hou N, et al. Predicting real-world effectiveness of Cancer therapies using overall survival and progression-free survival from clinical trials: empirical evidence for the ASCO value framework. Value Heal. 2017. https:\/\/doi.org\/10.1016\/j.jval.2017.04.003.","DOI":"10.1016\/j.jval.2017.04.003"},{"key":"6798_CR2","doi-asserted-by":"publisher","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","DOI":"10.1056\/NEJMoa1003466"},{"key":"6798_CR3","doi-asserted-by":"publisher","unstructured":"Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008. https:\/\/doi.org\/10.1200\/JCO.2007.12.7837.","DOI":"10.1200\/JCO.2007.12.7837"},{"key":"6798_CR4","doi-asserted-by":"publisher","unstructured":"McDermott D, Haanen J, Chen TT, Lorigan P, O\u2019Day S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013. https:\/\/doi.org\/10.1093\/annonc\/mdt291.","DOI":"10.1093\/annonc\/mdt291"},{"key":"6798_CR5","doi-asserted-by":"publisher","unstructured":"Polkowska M, Ekk-Cierniakowski P, Czepielewska E, Wysocza\u0144ski W, Matusewicz W, Koz\u0142owska-Wojciechowska M. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data. J Cancer Res Clin Oncol. 2017. https:\/\/doi.org\/10.1007\/s00432-017-2453-z.","DOI":"10.1007\/s00432-017-2453-z"},{"key":"6798_CR6","volume-title":"Annual demographic estimates : Canada","author":"S Canada","year":"2018","unstructured":"Statistics Canada. Annual demographic estimates : Canada, Provinces and Territories.; 2018."},{"key":"6798_CR7","doi-asserted-by":"publisher","unstructured":"Austin PC, Van Walraven C. The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins aggregated diagnosis groups to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011. https:\/\/doi.org\/10.1097\/MLR.0b013e318229360e.","DOI":"10.1097\/MLR.0b013e318229360e"},{"key":"6798_CR8","doi-asserted-by":"publisher","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.03.012.","DOI":"10.1016\/j.jclinepi.2004.03.012"},{"key":"6798_CR9","doi-asserted-by":"publisher","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","DOI":"10.1080\/00273171.2011.568786"},{"key":"6798_CR10","doi-asserted-by":"publisher","unstructured":"Jochems A, Leeneman B, Franken MG, et al. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in the Netherlands. Anti-Cancer Drugs. 2018. https:\/\/doi.org\/10.1097\/CAD.0000000000000629.","DOI":"10.1097\/CAD.0000000000000629"},{"key":"6798_CR11","doi-asserted-by":"publisher","unstructured":"Russi A, Damuzzo V, Chiumente M, et al. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. J Chemother. 2017. https:\/\/doi.org\/10.1080\/1120009X.2017.1311444.","DOI":"10.1080\/1120009X.2017.1311444"},{"key":"6798_CR12","doi-asserted-by":"publisher","unstructured":"Middleton MR, Dalle S, Claveau J, et al. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Med. 2016. https:\/\/doi.org\/10.1002\/cam4.717.","DOI":"10.1002\/cam4.717"},{"key":"6798_CR13","doi-asserted-by":"publisher","unstructured":"Khoja L, Atenafu EG, Ye Q, et al. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncol Lett. 2016. https:\/\/doi.org\/10.3892\/ol.2015.4069.","DOI":"10.3892\/ol.2015.4069"},{"key":"6798_CR14","unstructured":"Krajsov\u00e1 I, Arenberger P, Lakom\u00fd R, et al. Long-term survival with ipilimumab: experience from a national expanded access program for patients with melanoma. Anticancer Res. 2015;35(11):6303\u201310."},{"key":"6798_CR15","doi-asserted-by":"publisher","unstructured":"Drysdale E, Peng Y, Nguyen P, Baetz T, Hanna TP. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma. Melanoma Res. 2019. https:\/\/doi.org\/10.1097\/CMR.0000000000000582.","DOI":"10.1097\/CMR.0000000000000582"},{"key":"6798_CR16","doi-asserted-by":"publisher","unstructured":"Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015. https:\/\/doi.org\/10.1016\/S1470-2045(15)00083-2.","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"6798_CR17","doi-asserted-by":"publisher","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","DOI":"10.1056\/NEJMoa1503093"},{"key":"6798_CR18","doi-asserted-by":"publisher","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015. https:\/\/doi.org\/10.1056\/NEJMoa1412082.","DOI":"10.1056\/NEJMoa1412082"},{"key":"6798_CR19","doi-asserted-by":"publisher","unstructured":"Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016. https:\/\/doi.org\/10.1016\/S1470-2045(16)30366-7.","DOI":"10.1016\/S1470-2045(16)30366-7"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06798-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06798-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06798-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T19:40:33Z","timestamp":1618429233000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06798-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6798"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06798-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21605\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21605\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"17 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has received ethics approval from the Research Ethics Board of Sunnybrook Health Sciences Centre, Ontario, Canada.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"304"}}